Search results
Results From The WOW.Com Content Network
Carbohydrate antigen 19-9 ( CA19-9 ), also known as sialyl-LewisA, is a tetrasaccharide which is usually attached to O- glycans on the surface of cells. It is known to play a role in cell-to-cell recognition processes. It is also a tumor marker used primarily in the management of pancreatic cancer. [1]
Specialty. Oncology. A Klatskin tumor (or hilar cholangiocarcinoma) is a cholangiocarcinoma ( cancer of the biliary tree) occurring at the confluence of the right and left hepatic bile ducts. The disease was named after Gerald Klatskin, who in 1965 described 15 cases and found some characteristics for this type of cholangiocarcinoma [1] [2] [3]
CA19-9 (carbohydrate antigen 19.9) is a tumor marker that is frequently elevated in pancreatic cancer. However, it lacks sensitivity and specificity, not least because 5% of people lack the Lewis (a) antigen and cannot produce CA19-9. It has a sensitivity of 80% and specificity of 73% in detecting pancreatic adenocarcinoma, and is used for ...
Tumor marker. A tumor marker is a biomarker that can be used to indicate the presence of cancer or the behavior of cancers (measure progression or response to therapy). They can be found in bodily fluids or tissue. Markers can help with assessing prognosis, surveilling patients after surgical removal of tumors, and even predicting drug-response ...
The Lewis antigen system is a human blood group system. It is based upon two genes on chromosome 19: FUT3, or Lewis gene; and FUT2, or Secretor gene. Both genes are expressed in glandular epithelia. FUT2 has a dominant allele which codes for an enzyme (designated Se) and a recessive allele which does not produce a functional enzyme (designated se).
CA 242 is a tumor marker for sialylated Lewis carbohydrates associated with adenocarcinomas and e-selectin -mediated metastatic risk. [1] [2] [3] It is commonly tested along with CEA, CA19-9, and CA242 for detecting pancreatic cancer. [4] The specificity of CA 242 is higher than similar markers. Current research dictates that diagnostic ...
Since starting in 2019, Engle's lab has begun creating transgenic mouse models of pancreatic cancer that have tumors that express the uniquely human CA19-9 tumor antigen. This will allow the lab to better recapitulate the human tumor environment and move towards better diagnostics and treatments for pancreatic cancer. Awards and honours
Wednesday, September 9, 2009 Susan Weinstock (202) 387-6121 Jack Gillis (202) 737-0766 SURVEY: AMERICANS WANT CONSUMER AGENCY FOR FINANCIAL PRODUCTS AND SERVICES Consumers strongly support better disclosures, prohibitions on abusive practices. Washington, D.C.